DENVER, April 13, 2022 /CNW/ – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“ Mydecine” or the “Company“), today announces its Board of Directors has voted in favour of completing a reverse stock-split, thereby consolidating all of the Company’s issued and outstanding common shares (“Common Shares“) on the basis of one (1) post-consolidation Common Share for every fifty…


Previous articleCybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
Next articleCould the Sonoran Desert Toad Cure Narcissism?